Dual HER2 Targeted Therapy With Pyrotinib and Trastuzumab in Refractory HER2 Positive Metastatic Colorectal Cancer: A Result From HER2-FUSCC-G Study
العنوان: | Dual HER2 Targeted Therapy With Pyrotinib and Trastuzumab in Refractory HER2 Positive Metastatic Colorectal Cancer: A Result From HER2-FUSCC-G Study |
---|---|
المؤلفون: | Jinjia Chang, Midie Xu, Chenchen Wang, Dan Huang, Zhe Zhang, Zhiyu Chen, Xiaodong Zhu, Wenhua Li |
المصدر: | Clinical Colorectal Cancer. 21:347-353 |
بيانات النشر: | Elsevier BV, 2022. |
سنة النشر: | 2022 |
مصطلحات موضوعية: | Proto-Oncogene Proteins B-raf, Oncology, Receptor, ErbB-2, Rectal Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Colonic Neoplasms, Gastroenterology, Humans, Female, Breast Neoplasms, Trastuzumab, Colorectal Neoplasms |
الوصف: | Dual-HER2 targeted therapy has led to a promising antitumor effect in HER2 positive cancers including gastrointestinal cancer. The present data focus on patients with HER2 positive colorectal cancer who received pyrotinib and trastuzumab after failure to standard second-line treatment.Patients diagnosed of HER2 positive refractory or metastatic colorectal cancer were enrolled to receive trastuzumab in combination with pyrotinib as third-line and beyond therapy. Trastuzumab was given as a loading dose at 8 mg/kg followed by 6mg/kg once every 3 weeks, and oral pyrotinib as 400 mg per day until progression. ORR was set as the primary endpoint. PFS and OS were set as a secondary endpoints. This trial is registered with Clinical Trial.gov, NCT04960943, and is ongoing.Between February 2020 to December 2021, 16 patients including 14 with RAS wild-type status were enrolled in this cohort. ORR was 50.0% in the overall population, and 57.1% in RAS wild-type patients. At a median follow-up of 11.2 months, median PFS and OS were 7.53 and 16.8 months, respectively. The RAS/BRAF wild-type patients had prolonged survival (PFS: 7.53 vs. 1.63 months, P = .02; OS: NR vs.4.13 months, P = .001) compared with RAS/BRAF mutant patients. The most common treatment-emergent adverse event (TEAE) reported is diarrhea. Five (31.3%) patients reported grade 3 TEAEs, and no death was reported.Trastuzumab in combination with pyrotinib demonstrated encouraging antitumor activity that translated to prolonged survival benefit in HER2 positive refractory or mCRC patients who are RAS wild-type with acceptable tolerance. |
تدمد: | 1533-0028 |
URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51783d3671b3b0f96fb7780487913bde https://doi.org/10.1016/j.clcc.2022.07.003 |
حقوق: | CLOSED |
رقم الأكسشن: | edsair.doi.dedup.....51783d3671b3b0f96fb7780487913bde |
قاعدة البيانات: | OpenAIRE |
كن أول من يترك تعليقا!